secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-07-30T21:19:45+00:00
Accession:  0001326110-26-000071
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio gets UAE marketing authorization for ANKTIVA in bladder and lung cancers
--------------------------------------------------------------------------------

- UAE approved ANKTIVA for BCG-unresponsive NMIBC (CIS and papillary) and metastatic NSCLC after checkpoint failure.
- NMIBC CIS cohort (N=100): 71% complete response rate; median DoR 26.6 months, with responses beyond 54 months.
- Papillary-only cohort (N=80): 12-month disease-free survival 58.2%; 83.1% cystectomy-free at 36 months.
- NSCLC checkpoint-refractory (N=79): median OS 14.6 months; 16.2 months in patients with ALC ≥1,000.
- Authorization expands ANKTIVA's global regulatory footprint to 34 countries; validity through July 2031.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000071/0001326110-26-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000071/ibrx-20260729.htm
  HTML page:      https://secwatch.observer/filing/0001326110-26-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer